{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:34:44Z","timestamp":1793932484842,"version":"4.8.0"},"reference-count":230,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/nrneurol.2017.148","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T23:13:20Z","timestamp":1512083600000},"page":"9-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":787,"title":["Antisense oligonucleotides: the next frontier for treatment of neurological disorders"],"prefix":"10.1038","volume":"14","author":[{"given":"Carlo","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J. A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"key":"BFnrneurol2017148_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","volume":"75","author":"ML Stephenson","year":"1978","unstructured":"Stephenson, M. L. & Zamecnik, P. C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl Acad. Sci. USA 75, 285\u2013288 (1978).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrd3459","volume":"10","author":"F Muntoni","year":"2011","unstructured":"Muntoni, F. & Wood, M. J. A. Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug Discov. 10, 621\u2013637 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrneurol2017148_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nrd837","volume":"1","author":"JB Opalinska","year":"2002","unstructured":"Opalinska, J. B. & Gewirtz, A. M. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503\u2013514 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrneurol2017148_CR4","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"RL Juliano","year":"2016","unstructured":"Juliano, R. L. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 44, 6518\u20136548 (2016).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4161\/cbt.1.4.4","volume":"1","author":"N Dias","year":"2002","unstructured":"Dias, N. & Stein, C. A. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 1, 347\u2013355 (2002).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrneurol2017148_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/ard.1991.1.141","volume":"1","author":"PS Eder","year":"1991","unstructured":"Eder, P. S., DeVine, R. J., Dagle, J. M. & Walder, J. A. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3\u2032 exonuclease in plasma. Antisense Res. Dev. 1, 141\u2013151 (1991).","journal-title":"Antisense Res. Dev."},{"key":"BFnrneurol2017148_CR7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1126\/science.165.3898.1137","volume":"165","author":"E De Clercq","year":"1969","unstructured":"De Clercq, E., Eckstein, E. & Merigan, T. C. Interferon induction increased through chemical modification of a synthetic polyribonucleotide. Science 165, 1137\u20131139 (1969).","journal-title":"Science"},{"key":"BFnrneurol2017148_CR8","first-page":"717","volume":"149","author":"A Rifai","year":"1996","unstructured":"Rifai, A., Brysch, W., Fadden, K., Clark, J. & Schlingensiepen, K. H. Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am. J. Pathol. 149, 717\u2013725 (1996).","journal-title":"Am. J. Pathol."},{"key":"BFnrneurol2017148_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/oli.2006.16.169","volume":"16","author":"TA Watanabe","year":"2006","unstructured":"Watanabe, T. A., Geary, R. S. & Levin, A. A. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 16, 169\u2013180 (2006).","journal-title":"Oligonucleotides"},{"key":"BFnrneurol2017148_CR10","doi-asserted-by":"publisher","first-page":"17181","DOI":"10.1074\/jbc.M311683200","volume":"279","author":"H Wu","year":"2004","unstructured":"Wu, H. et al. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 279, 17181\u201317189 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2017148_CR11","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1093\/nar\/25.22.4429","volume":"25","author":"SM Freier","year":"1997","unstructured":"Freier, S. M. & Altmann, K. H. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 25, 4429\u20134443 (1997).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/1074-5521(94)90039-6","volume":"1","author":"P Lubini","year":"1994","unstructured":"Lubini, P., Z\u00fcrcher, W. & Egli, M. Stabilizing effects of the RNA 2\u2032-substituent: crystal structure of an oligodeoxynucleotide duplex containing 2\u2032-O-methylated adenosines. Chem. Biol. 1, 39\u201345 (1994).","journal-title":"Chem. Biol."},{"key":"BFnrneurol2017148_CR13","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1074\/jbc.274.3.1715","volume":"274","author":"RA McKay","year":"1999","unstructured":"McKay, R. A. et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J. Biol. Chem. 274, 1715\u20131722 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2017148_CR14","first-page":"562","volume":"2","author":"RS Geary","year":"2001","unstructured":"Geary, R. S., Yu, R. Z. & Levin, A. A. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs 2, 562\u2013573 (2001).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnrneurol2017148_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.imbio.2009.09.003","volume":"215","author":"S Hamm","year":"2010","unstructured":"Hamm, S. et al. Alternating 2\u2032-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology 215, 559\u2013569 (2010).","journal-title":"Immunobiology"},{"key":"BFnrneurol2017148_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/oli.1.1997.7.63","volume":"7","author":"J Summerton","year":"1997","unstructured":"Summerton, J. et al. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev. 7, 63\u201370 (1997).","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"BFnrneurol2017148_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","volume":"6","author":"RM Hudziak","year":"1996","unstructured":"Hudziak, R. M. et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6, 267\u2013272 (1996).","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"BFnrneurol2017148_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1517\/17425250902877680","volume":"5","author":"RS Geary","year":"2009","unstructured":"Geary, R. S. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin. Drug Metab. Toxicol. 5, 381\u2013391 (2009).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"BFnrneurol2017148_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1517\/17425255.2013.737320","volume":"9","author":"RZ Yu","year":"2013","unstructured":"Yu, R. Z., Grundy, J. S. & Geary, R. S. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin. Drug Metab. Toxicol. 9, 169\u2013182 (2013).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"BFnrneurol2017148_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","volume":"76","author":"ST Crooke","year":"2013","unstructured":"Crooke, S. T. & Geary, R. S. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br. J. Clin. Pharmacol. 76, 269\u2013276 (2013).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrneurol2017148_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.crad.2007.10.007","volume":"63","author":"AA Levin","year":"2008","unstructured":"Levin, A. A., Levine, M. S., Rubesin, S. E. & Laufer, I. An 8-year review of barium studies in the diagnosis of gastroparesis. Clin. Radiol. 63, 407\u2013414 (2008).","journal-title":"Clin. Radiol."},{"key":"BFnrneurol2017148_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.coph.2005.07.001","volume":"5","author":"A Amantana","year":"2005","unstructured":"Amantana, A. & Iversen, P. L. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr. Opin. Pharmacol. 5, 550\u2013555 (2005).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFnrneurol2017148_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/nat.2012.0371","volume":"22","author":"JD Thompson","year":"2012","unstructured":"Thompson, J. D. et al. Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Nucleic Acid Ther. 22, 255\u2013264 (2012).","journal-title":"Nucleic Acid Ther."},{"key":"BFnrneurol2017148_CR24","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.bcp.2008.11.005","volume":"77","author":"RZ Yu","year":"2009","unstructured":"Yu, R. Z. et al. Cross-species comparison of in vivo PK\/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem. Pharmacol. 77, 910\u2013919 (2009).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrneurol2017148_CR25","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/78475","volume":"18","author":"H Zhang","year":"2000","unstructured":"Zhang, H. et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 18, 862\u2013867 (2000).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol2017148_CR26","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1042\/bst0240630","volume":"24","author":"KH Altmann","year":"1996","unstructured":"Altmann, K. H. et al. Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem. Soc. Trans. 24, 630\u2013637 (1996).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrneurol2017148_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/nat.2013.0443","volume":"23","author":"G Hung","year":"2013","unstructured":"Hung, G. et al. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther. 23, 369\u2013378 (2013).","journal-title":"Nucleic Acid Ther."},{"key":"BFnrneurol2017148_CR28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0006-2952(97)00190-1","volume":"54","author":"JA Phillips","year":"1997","unstructured":"Phillips, J. A. et al. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54, 657\u2013668 (1997).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrneurol2017148_CR29","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/JCI25424","volume":"116","author":"RA Smith","year":"2006","unstructured":"Smith, R. A. et al. Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 2290\u20132296 (2006).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2017148_CR30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington's Disease by transient repression of Huntingtin synthesis. Neuron 74, 1031\u20131044 (2012).","journal-title":"Neuron"},{"key":"BFnrneurol2017148_CR31","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini, M. A. et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl Med. 3, 72ra18 (2011).","journal-title":"Sci. Transl Med."},{"key":"BFnrneurol2017148_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1124\/jpet.113.212407","volume":"350","author":"F Rigo","year":"2014","unstructured":"Rigo, F. et al. Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350, 46\u201355 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrneurol2017148_CR33","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.molmed.2012.09.001","volume":"18","author":"AL Southwell","year":"2012","unstructured":"Southwell, A. L., Skotte, N. H., Bennett, C. F. & Hayden, M. R. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol. Med. 18, 634\u2013643 (2012).","journal-title":"Trends Mol. Med."},{"key":"BFnrneurol2017148_CR34","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel, R. S. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388, 3017\u20133026 (2016).","journal-title":"Lancet"},{"key":"BFnrneurol2017148_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller, T. M. et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12, 435\u2013442 (2013).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2017148_CR36","doi-asserted-by":"publisher","first-page":"9634","DOI":"10.1093\/nar\/gkt725","volume":"41","author":"ME Ostergaard","year":"2013","unstructured":"Ostergaard, M. E. et al. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res. 41, 9634\u20139650 (2013).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR37","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga, C. A. et al. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 86, 890\u2013897 (2016).","journal-title":"Neurology"},{"key":"BFnrneurol2017148_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm1345","volume":"12","author":"J Alter","year":"2006","unstructured":"Alter, J. et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12, 175\u2013177 (2006).","journal-title":"Nat. Med."},{"key":"BFnrneurol2017148_CR39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/nm0497-414","volume":"3","author":"L Benimetskaya","year":"1997","unstructured":"Benimetskaya, L. et al. Mac-1 (CD11b\/CD18) is an oligodeoxynucleotide-binding protein. Nat. Med. 3, 414\u2013420 (1997).","journal-title":"Nat. Med."},{"key":"BFnrneurol2017148_CR40","first-page":"379","volume":"77","author":"M Butler","year":"1997","unstructured":"Butler, M., Stecker, K. & Bennett, C. F. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. 77, 379\u2013388 (1997).","journal-title":"Lab. Invest."},{"key":"BFnrneurol2017148_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/oli.2009.0180","volume":"19","author":"M Robbins","year":"2009","unstructured":"Robbins, M., Judge, A. & MacLachlan, I. siRNA and innate immunity. Oligonucleotides 19, 89\u2013102 (2009).","journal-title":"Oligonucleotides"},{"key":"BFnrneurol2017148_CR42","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","volume":"34","author":"T Kawai","year":"2011","unstructured":"Kawai, T. & Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637\u2013650 (2011).","journal-title":"Immunity"},{"key":"BFnrneurol2017148_CR43","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1564","volume":"27","author":"M Kortylewski","year":"2009","unstructured":"Kortylewski, M. et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27, 925\u2013932 (2009).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol2017148_CR44","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/nar\/28.2.582","volume":"28","author":"P Lorenz","year":"2000","unstructured":"Lorenz, P., Misteli, T., Baker, B. F., Bennett, C. F. & Spector, D. L. Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 28, 582\u2013592 (2000).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR45","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1768-322X.1998.tb01050.x","volume":"90","author":"R Hartig","year":"1998","unstructured":"Hartig, R., Shoeman, R. L., Janetzko, A., Gr\u00fcb, S. & Traub, P. Active nuclear import of single-stranded oligonucleotides and their complexes with non-karyophilic macromolecules. Biol. Cell 90, 407\u2013426 (1998).","journal-title":"Biol. Cell"},{"key":"BFnrneurol2017148_CR46","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.004","volume":"151","author":"AK Varkouhi","year":"2011","unstructured":"Varkouhi, A. K., Scholte, M., Storm, G. & Haisma, H. J. Endosomal escape pathways for delivery of biologicals. J. Control. Release 151, 220\u2013228 (2011).","journal-title":"J. Control. Release"},{"key":"BFnrneurol2017148_CR47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1021\/bc200377d","volume":"23","author":"RL Juliano","year":"2012","unstructured":"Juliano, R. L., Ming, X. & Nakagawa, O. Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug. Chem. 23, 147\u2013157 (2012).","journal-title":"Bioconjug. Chem."},{"key":"BFnrneurol2017148_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.addr.2015.04.005","volume":"87","author":"RL Juliano","year":"2015","unstructured":"Juliano, R. L. & Carver, K. Cellular uptake and intracellular trafficking of oligonucleotides. Adv. Drug Deliv. Rev. 87, 35\u201345 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"BFnrneurol2017148_CR49","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/nar\/gku1367","volume":"43","author":"TR Wagenaar","year":"2015","unstructured":"Wagenaar, T. R. et al. Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cells. Nucleic Acids Res. 43, 1204\u20131215 (2015).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR50","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1021\/acs.biomac.5b01334","volume":"17","author":"M Tangsangasaksri","year":"2016","unstructured":"Tangsangasaksri, M. et al. siRNA-loaded polyion complex micelle decorated with charge-conversional polymer tuned to undergo stepwise response to intra-tumoral and intra-endosomal pHs for exerting enhanced RNAi efficacy. Biomacromolecules 17, 246\u2013255 (2016).","journal-title":"Biomacromolecules"},{"key":"BFnrneurol2017148_CR51","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/nar\/gkv060","volume":"43","author":"B Yang","year":"2015","unstructured":"Yang, B. et al. High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides. Nucleic Acids Res. 43, 1987\u20131996 (2015).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR52","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1093\/nar\/gkt1414","volume":"42","author":"KA Majorek","year":"2014","unstructured":"Majorek, K. A. et al. The RNase H-like superfamily: new members, comparative structural analysis and evolutionary classification. Nucleic Acids Res. 42, 4160\u20134179 (2014).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR53","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1093\/nar\/gkw065","volume":"44","author":"WF Lima","year":"2016","unstructured":"Lima, W. F., De Hoyos, C. L., Liang, X. & Crooke, S. T. RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery. Nucleic Acids Res. 44, 3351\u20133363 (2016).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR54","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.chembiol.2012.07.011","volume":"19","author":"GF Deleavey","year":"2012","unstructured":"Deleavey, G. F. & Damha, M. J. Designing chemically modified oligonucleotides for targeted gene silencing. Chem. Biol. 19, 937\u2013954 (2012).","journal-title":"Chem. Biol."},{"key":"BFnrneurol2017148_CR55","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","volume":"268","author":"BP Monia","year":"1993","unstructured":"Monia, B. P. et al. Evaluation of 2\u2032-modified oligonucleotides containing 2\u2032-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514\u201314522 (1993).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2017148_CR56","doi-asserted-by":"publisher","first-page":"28270","DOI":"10.1074\/jbc.274.40.28270","volume":"274","author":"H Wu","year":"1999","unstructured":"Wu, H., Lima, W. F. & Crooke, S. T. Properties of cloned and expressed human RNase H1. J. Biol. Chem. 274, 28270\u201328278 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2017148_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/1074-5521(94)90014-0","volume":"1","author":"RR Breaker","year":"1994","unstructured":"Breaker, R. R. & Joyce, G. F. A. DNA enzyme that cleaves RNA. Chem. Biol. 1, 223\u2013229 (1994).","journal-title":"Chem. Biol."},{"key":"BFnrneurol2017148_CR58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/372039a0","volume":"372","author":"TR Cech","year":"1994","unstructured":"Cech, T. R. & Uhlenbeck, O. C. Hammerhead nailed down. Nature 372, 39\u201340 (1994).","journal-title":"Nature"},{"key":"BFnrneurol2017148_CR59","doi-asserted-by":"publisher","first-page":"11994","DOI":"10.1074\/jbc.272.18.11994","volume":"272","author":"BF Baker","year":"1997","unstructured":"Baker, B. F. et al. 2\u2032-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272, 11994\u201312000 (1997).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2017148_CR60","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","volume":"87","author":"MM Evers","year":"2015","unstructured":"Evers, M. M., Toonen, L. J. A. & van Roon-Mom, W. M. C. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv. Drug Deliv. Rev. 87, 90\u2013103 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"BFnrneurol2017148_CR61","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1093\/nar\/gkw533","volume":"44","author":"MA Havens","year":"2016","unstructured":"Havens, M. A. & Hastings, M. L. SURVEY AND SUMMARY Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 44, 6549\u20136563 (2016).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR62","unstructured":"US Food and Drug Administration. FDA approves first drug for spinal muscular atrophy. US Food and Drug Administration https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm534611.htm (2016)."},{"key":"BFnrneurol2017148_CR63","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/nar\/29.6.1293","volume":"29","author":"TA Vickers","year":"2001","unstructured":"Vickers, T. A., Wyatt, J. R., Burckin, T., Bennett, C. F. & Freier, S. M. Fully modified 2' MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res. 29, 1293\u20131299 (2001).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR64","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","volume":"90","author":"Z Dominski","year":"1993","unstructured":"Dominski, Z. & Kole, R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl Acad. Sci. USA 90, 8673\u20138677 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR65","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","volume":"24","author":"JK Mah","year":"2014","unstructured":"Mah, J. K. et al. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul. Disord. 24, 482\u2013491 (2014).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrneurol2017148_CR66","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1242\/jcs.02857","volume":"119","author":"LM Judge","year":"2006","unstructured":"Judge, L. M., Haraguchiln, M. & Chamberlain, J. S. Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. J. Cell Sci. 119, 1537\u20131546 (2006).","journal-title":"J. Cell Sci."},{"key":"BFnrneurol2017148_CR67","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/qjmed\/hci113","volume":"98","author":"AE Parker","year":"2005","unstructured":"Parker, A. E. et al. Analysis of an adult Duchenne muscular dystrophy population. QJM 98, 729\u2013736 (2005).","journal-title":"QJM"},{"key":"BFnrneurol2017148_CR68","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","volume":"16","author":"S Guiraud","year":"2015","unstructured":"Guiraud, S. et al. The pathogenesis and therapy of muscular dystrophies. Annu. Rev. Genomics Hum. Genet. 16, 281\u2013308 (2015).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"BFnrneurol2017148_CR69","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nrm2024","volume":"7","author":"KE Davies","year":"2006","unstructured":"Davies, K. E. & Nowak, K. J. Molecular mechanisms of muscular dystrophies: old and new players. Nat. Rev. Mol. Cell Biol. 7, 762\u2013773 (2006).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"BFnrneurol2017148_CR70","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman, E. P., Brown, R. H. & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919\u2013928 (1987).","journal-title":"Cell"},{"key":"BFnrneurol2017148_CR71","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen, C. L. et al. The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395\u2013402 (2015).","journal-title":"Hum. Mutat."},{"key":"BFnrneurol2017148_CR72","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/hmg\/7.7.1083","volume":"7","author":"MG Dunckley","year":"1998","unstructured":"Dunckley, M. G., Manoharan, M., Villiet, P., Eperon, I. C. & Dickson, G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum. Mol. Genet. 7, 1083\u20131090 (1998).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol2017148_CR73","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1006\/bbrc.1996.1375","volume":"226","author":"ZA Pramono","year":"1996","unstructured":"Pramono, Z. A. et al. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem. Biophys. Res. Commun. 226, 445\u2013449 (1996).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrneurol2017148_CR74","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/JCI117693","volume":"95","author":"Y Takeshima","year":"1995","unstructured":"Takeshima, Y., Nishio, H., Sakamoto, H., Nakamura, H. & Matsuo, M. Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J. Clin. Invest. 95, 515\u2013520 (1995).","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 1","key":"BFnrneurol2017148_CR75","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/S0960-8966(02)00086-X","volume":"12","author":"A Aartsma-Rus","year":"2002","unstructured":"Aartsma-Rus, A. et al. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12 (Suppl. 1), S71\u2013S77 (2002).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrneurol2017148_CR76","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.gt.3302313","volume":"11","author":"A Aartsma-Rus","year":"2004","unstructured":"Aartsma-Rus, A. et al. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther. 11, 1391\u20131398 (2004).","journal-title":"Gene Ther."},{"key":"BFnrneurol2017148_CR77","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nmd.2009.10.013","volume":"20","author":"LJ Popplewell","year":"2010","unstructured":"Popplewell, L. J. et al. Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials. Neuromuscul. Disord. 20, 102\u2013110 (2010).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrneurol2017148_CR78","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/mt.2008.287","volume":"17","author":"LJ Popplewell","year":"2009","unstructured":"Popplewell, L. J., Trollet, C., Dickson, G. & Graham, I. R. Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol. Ther. 17, 554\u2013561 (2009).","journal-title":"Mol. Ther."},{"key":"BFnrneurol2017148_CR79","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/hmg\/10.15.1547","volume":"10","author":"JC van Deutekom","year":"2001","unstructured":"van Deutekom, J. C. et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet. 10, 1547\u20131554 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol2017148_CR80","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nrg1180","volume":"4","author":"JCT van Deutekom","year":"2003","unstructured":"van Deutekom, J. C. T. & van Ommen, G.-J. B. Advances in Duchenne muscular dystrophy gene therapy. Nat. Rev. Genet. 4, 774\u2013783 (2003).","journal-title":"Nat. Rev. Genet."},{"key":"BFnrneurol2017148_CR81","first-page":"179","volume":"26","author":"T Yokota","year":"2007","unstructured":"Yokota, T., Duddy, W. & Partridge, T. Optimizing exon skipping therapies for DMD. Acta Myol. 26, 179\u2013184 (2007).","journal-title":"Acta Myol."},{"key":"BFnrneurol2017148_CR82","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu, Q. L. et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl Acad. Sci. USA 102, 198\u2013203 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR83","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/mt.2010.72","volume":"18","author":"H Heemskerk","year":"2010","unstructured":"Heemskerk, H. et al. Preclinical PK and PD studies on 2\u2032-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol. Ther. 18, 1210\u20131217 (2010).","journal-title":"Mol. Ther."},{"key":"BFnrneurol2017148_CR84","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/jgm.1288","volume":"11","author":"HA Heemskerk","year":"2009","unstructured":"Heemskerk, H. A. et al. In vivo comparison of 2\u2032-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J. Gene Med. 11, 257\u2013266 (2009).","journal-title":"J. Gene Med."},{"key":"BFnrneurol2017148_CR85","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-1-61737-982-6_20","volume":"709","author":"T Yokota","year":"2011","unstructured":"Yokota, T., Hoffman, E. & Takeda, S. Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy. Methods Mol. Biol. 709, 299\u2013312 (2011).","journal-title":"Methods Mol. Biol."},{"key":"BFnrneurol2017148_CR86","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/nat.2011.0306","volume":"21","author":"A Malerba","year":"2011","unstructured":"Malerba, A., Boldrin, L. & Dickson, G. Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Nucleic Acid. Ther. 21, 293\u2013298 (2011).","journal-title":"Nucleic Acid. Ther."},{"key":"BFnrneurol2017148_CR87","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/mt.2008.52","volume":"16","author":"D Townsend","year":"2008","unstructured":"Townsend, D., Yasuda, S., Li, S., Chamberlain, J. S. & Metzger, J. M. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol. Ther. 16, 832\u2013835 (2008).","journal-title":"Mol. Ther."},{"key":"BFnrneurol2017148_CR88","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","volume":"378","author":"S Cirak","year":"2011","unstructured":"Cirak, S. et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378, 595\u2013605 (2011).","journal-title":"Lancet"},{"key":"BFnrneurol2017148_CR89","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell, J. R. et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637\u2013647 (2013).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2017148_CR90","unstructured":"Sarepta Therapeutics, Inc. PCNSD Advisory Committee Meeting Briefing Document. U.S. Food and Drug Administration https:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/peripheralandcentralnervoussystemdrugsadvisorycommittee\/ucm497064.pdf (2017)."},{"key":"BFnrneurol2017148_CR91","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. US Food and Drug Administration https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm521263.htm (2016)."},{"key":"BFnrneurol2017148_CR92","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2016.16437","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim, A. S. & Avorn, J. Approving a problematic muscular dystrophy drug. JAMA 316, 2357 (2016).","journal-title":"JAMA"},{"key":"BFnrneurol2017148_CR93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nbt0104-3","volume":"22","author":"S Pearson","year":"2004","unstructured":"Pearson, S., Jia, H. & Kandachi, K. China approves first gene therapy. Nat. Biotechnol. 22, 3\u20134 (2004).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol2017148_CR94","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fnmol.2015.00032","volume":"8","author":"SA Hoyng","year":"2015","unstructured":"Hoyng, S. A. et al. Gene therapy and peripheral nerve repair: a perspective. Front. Mol. Neurosci. 8, 32 (2015).","journal-title":"Front. Mol. Neurosci."},{"key":"BFnrneurol2017148_CR95","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrd2399","volume":"7","author":"B Leader","year":"2008","unstructured":"Leader, B., Baca, Q. J. & Golan, D. E. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7, 21\u201339 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrneurol2017148_CR96","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nbt.3589","volume":"34","author":"X Liang","year":"2016","unstructured":"Liang, X. et al. Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nat. Biotechnol. 34, 875\u2013880 (2016).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol2017148_CR97","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1073\/pnas.0810916106","volume":"106","author":"SE Calvo","year":"2009","unstructured":"Calvo, S. E., Pagliarini, D. J. & Mootha, V. K. Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans. Proc. Natl Acad. Sci. USA 106, 7507\u20137512 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR98","doi-asserted-by":"publisher","first-page":"E2424","DOI":"10.1073\/pnas.1207846109","volume":"109","author":"S Lee","year":"2012","unstructured":"Lee, S. et al. Global mapping of translation initiation sites in mammalian cells at single-nucleotide resolution. Proc. Natl Acad. Sci. USA 109, E2424\u2013E2432 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR99","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1146\/annurev.neuro.29.051605.113042","volume":"30","author":"HT Orr","year":"2007","unstructured":"Orr, H. T. & Zoghbi, H. Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575\u2013621 (2007).","journal-title":"Annu. Rev. Neurosci."},{"key":"BFnrneurol2017148_CR100","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","volume":"90","author":"SW Davies","year":"1997","unstructured":"Davies, S. W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537\u2013548 (1997).","journal-title":"Cell"},{"key":"BFnrneurol2017148_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-012-1000-x","volume":"124","author":"K Seidel","year":"2012","unstructured":"Seidel, K. et al. Brain pathology of spinocerebellar ataxias. Acta Neuropathol. 124, 1\u201321 (2012).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2017148_CR102","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nbt.1539","volume":"27","author":"J Hu","year":"2009","unstructured":"Hu, J. et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol. 27, 478\u2013484 (2009).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol2017148_CR103","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.chembiol.2010.10.013","volume":"17","author":"J Hu","year":"2010","unstructured":"Hu, J., Liu, J. & Corey, D. R. Allele-selective inhibition of Huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem. Biol. 17, 1183\u20131188 (2010).","journal-title":"Chem. Biol."},{"key":"BFnrneurol2017148_CR104","doi-asserted-by":"publisher","first-page":"10166","DOI":"10.1021\/bi101208k","volume":"49","author":"KT Gagnon","year":"2010","unstructured":"Gagnon, K. T. et al. Allele-selective inhibition of mutant Huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 49, 10166\u201310178 (2010).","journal-title":"Biochemistry"},{"key":"BFnrneurol2017148_CR105","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1093\/hmg\/ddu349","volume":"23","author":"X Sun","year":"2014","unstructured":"Sun, X. et al. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. Hum. Mol. Genet. 23, 6302\u20136317 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol2017148_CR106","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1089\/hum.2007.116","volume":"19","author":"PHJ van Bilsen","year":"2008","unstructured":"van Bilsen, P. H. J. et al. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum. Gene Ther. 19, 710\u2013718 (2008).","journal-title":"Hum. Gene Ther."},{"key":"BFnrneurol2017148_CR107","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","volume":"217","author":"MS Lombardi","year":"2009","unstructured":"Lombardi, M. S. et al. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol. 217, 312\u2013319 (2009).","journal-title":"Exp. Neurol."},{"key":"BFnrneurol2017148_CR108","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/mt.2011.201","volume":"19","author":"JB Carroll","year":"2011","unstructured":"Carroll, J. B. et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/ allele-specific silencing of mutant huntingtin. Mol. Ther. 19, 2178\u20132185 (2011).","journal-title":"Mol. Ther."},{"key":"BFnrneurol2017148_CR109","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","volume":"84","author":"SC Warby","year":"2009","unstructured":"Warby, S. C. et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am. J. Hum. Genet. 84, 351\u2013366 (2009).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrneurol2017148_CR110","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister, E. L. et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. 19, 774\u2013778 (2009).","journal-title":"Curr. Biol."},{"key":"BFnrneurol2017148_CR111","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen, D. R. et al. Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59\u201362 (1993).","journal-title":"Nature"},{"key":"BFnrneurol2017148_CR112","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamaneurol.2013.593","volume":"70","author":"L Winer","year":"2013","unstructured":"Winer, L. et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 70, 201\u2013207 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol2017148_CR113","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1172\/JCI80705","volume":"125","author":"MJ Crisp","year":"2015","unstructured":"Crisp, M. J. et al. In vivo kinetic approach reveals slow SOD1 turnover in the CNS. J. Clin. Invest. 125, 2772\u20132780 (2015).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2017148_CR114","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-3-540-34449-0_5","volume":"44","author":"A Andreadis","year":"2006","unstructured":"Andreadis, A. Misregulation of tau alternative splicing in neurodegeneration and dementia. Prog. Mol. Subcell. Biol. 44, 89\u2013107 (2006).","journal-title":"Prog. Mol. Subcell. Biol."},{"key":"BFnrneurol2017148_CR115","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.3122323","volume":"239","author":"G Lee","year":"1988","unstructured":"Lee, G., Cowan, N. & Kirschner, M. The primary structure and heterogeneity of tau protein from mouse brain. Science 239, 285\u2013288 (1988).","journal-title":"Science"},{"key":"BFnrneurol2017148_CR116","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1016\/S0021-9258(17)42989-9","volume":"259","author":"G Lindwall","year":"1984","unstructured":"Lindwall, G. & Cole, R. D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259, 5301\u20135305 (1984).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2017148_CR117","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1073\/pnas.91.12.5562","volume":"91","author":"AC Alonso","year":"1994","unstructured":"Alonso, A. C., Zaidi, T., Grundke-Iqbal, I. & Iqbal, K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl Acad. Sci. USA 91, 5562\u20135566 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR118","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal, I. et al. Abnormal phosphorylation of the microtubule-associated protein \u03c4 (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913\u20134917 (1986).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR119","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0140-6736(86)92134-3","volume":"2","author":"K Iqbal","year":"1986","unstructured":"Iqbal, K. et al. Defective brain microtubule assembly in Alzheimer's disease. Lancet 2, 421\u2013426 (1986).","journal-title":"Lancet"},{"key":"BFnrneurol2017148_CR120","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2017148_CR121","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0022-510X(70)90063-8","volume":"11","author":"BE Tomlinson","year":"1970","unstructured":"Tomlinson, B. E., Blessed, G. & Roth, M. Observations on the brains of demented old people. J. Neurol. Sci. 11, 205\u2013242 (1970).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol2017148_CR122","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF00688184","volume":"74","author":"I Alafuzoff","year":"1987","unstructured":"Alafuzoff, I., Iqbal, K., Friden, H., Adolfsson, R. & Winblad, B. Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol. 74, 209\u2013225 (1987).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2017148_CR123","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1212\/WNL.42.3.631","volume":"42","author":"PV Arriagada","year":"1992","unstructured":"Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T. & Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631\u2013639 (1992).","journal-title":"Neurology"},{"key":"BFnrneurol2017148_CR124","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1126\/science.6474172","volume":"225","author":"BT Hyman","year":"1984","unstructured":"Hyman, B. T., Van Hoesen, G. W., Damasio, A. R. & Barnes, C. L. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225, 1168\u20131170 (1984).","journal-title":"Science"},{"key":"BFnrneurol2017148_CR125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm.2613","volume":"18","author":"P Lei","year":"2012","unstructured":"Lei, P. et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18, 291\u2013295 (2012).","journal-title":"Nat. Med."},{"key":"BFnrneurol2017148_CR126","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.neurobiolaging.2012.12.003","volume":"34","author":"M Morris","year":"2013","unstructured":"Morris, M. et al. Age-appropriate cognition and subtle dopamine-independent motor deficits in aged Tau knockout mice. Neurobiol. Aging 34, 1523\u20131529 (2013).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2017148_CR127","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1016\/j.neurobiolaging.2014.05.001","volume":"35","author":"Z Li","year":"2014","unstructured":"Li, Z., Hall, A. M., Kelinske, M. & Roberson, E. D. Seizure resistance without parkinsonism in aged mice after tau reduction. Neurobiol. Aging 35, 2617\u20132624 (2014).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol2017148_CR128","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1126\/science.1141736","volume":"316","author":"ED Roberson","year":"2007","unstructured":"Roberson, E. D. et al. Reducing endogenous tau ameliorates amyloid \u03b2-induced deficits in an Alzheimer's disease mouse model. Science 316, 750\u2013754 (2007).","journal-title":"Science"},{"key":"BFnrneurol2017148_CR129","doi-asserted-by":"publisher","first-page":"e0163236","DOI":"10.1371\/journal.pone.0163236","volume":"11","author":"A van Hummel","year":"2016","unstructured":"van Hummel, A. et al. No overt deficits in aged tau-deficient C57Bl\/6.Mapttm1(EGFP)Kit GFP knockin mice. PLoS ONE 11, e0163236 (2016).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2017148_CR130","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s13311-013-0194-5","volume":"10","author":"SL DeVos","year":"2013","unstructured":"DeVos, S. L. & Miller, T. M. Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics 10, 486\u2013497 (2013).","journal-title":"Neurotherapeutics"},{"key":"BFnrneurol2017148_CR131","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1038\/mtna.2014.30","volume":"3","author":"R Sud","year":"2014","unstructured":"Sud, R., Geller, E. T. & Schellenberg, G. D. Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies. Mol. Ther. Nucleic Acids 3, e180 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"BFnrneurol2017148_CR132","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337\u2013351 (2007).","journal-title":"Neuron"},{"key":"BFnrneurol2017148_CR133","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL DeVos","year":"2017","unstructured":"DeVos, S. L. et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl Med. 9, eaag0481 (2017).","journal-title":"Sci. Transl Med."},{"key":"BFnrneurol2017148_CR134","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.neuron.2016.04.042","volume":"90","author":"KM Schoch","year":"2016","unstructured":"Schoch, K. M. et al. Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron 90, 941\u2013947 (2016).","journal-title":"Neuron"},{"key":"BFnrneurol2017148_CR135","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","volume":"13","author":"H Jiang","year":"2004","unstructured":"Jiang, H., Mankodi, A., Swanson, M. S., Moxley, R. T. & Thornton, C. A. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 13, 3079\u20133088 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol2017148_CR136","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/ng1857","volume":"38","author":"MS Mahadevan","year":"2006","unstructured":"Mahadevan, M. S. et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat. Genet. 38, 1066\u20131070 (2006).","journal-title":"Nat. Genet."},{"key":"BFnrneurol2017148_CR137","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.neuro.29.051605.113014","volume":"29","author":"LPW Ranum","year":"2006","unstructured":"Ranum, L. P. W. & Cooper, T. A. RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci. 29, 259\u2013277 (2006).","journal-title":"Annu. Rev. Neurosci."},{"key":"BFnrneurol2017148_CR138","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1073\/pnas.0708519105","volume":"105","author":"JP Orengo","year":"2008","unstructured":"Orengo, J. P. et al. Expanded CTG repeats within the DMPK 3\u2032 UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc. Natl Acad. Sci. USA 105, 2646\u20132651 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR139","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/ng.2007.28","volume":"40","author":"RS Yadava","year":"2008","unstructured":"Yadava, R. S. et al. RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat. Genet. 40, 61\u201368 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrneurol2017148_CR140","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1212\/01.WNL.0000054481.84978.F9","volume":"60","author":"JW Day","year":"2003","unstructured":"Day, J. W. et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 60, 657\u2013664 (2003).","journal-title":"Neurology"},{"key":"BFnrneurol2017148_CR141","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1086\/378720","volume":"73","author":"CL Liquori","year":"2003","unstructured":"Liquori, C. L. et al. Myotonic dystrophy Type 2: human founder haplotype and evolutionary conservation of the repeat tract. Am. J. Hum. Genet. 73, 849\u2013862 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrneurol2017148_CR142","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/hmg\/ddl103","volume":"15","author":"JM Margolis","year":"2006","unstructured":"Margolis, J. M., Schoser, B. G., Moseley, M. L., Day, J. W. & Ranum, L. P. W. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum. Mol. Genet. 15, 1808\u20131815 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol2017148_CR143","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1042\/BST0371281","volume":"37","author":"JE Lee","year":"2009","unstructured":"Lee, J. E. & Cooper, T. A. Pathogenic mechanisms of myotonic dystrophy. Biochem. Soc. Trans. 37, 1281\u20131286 (2009).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrneurol2017148_CR144","doi-asserted-by":"publisher","first-page":"31079","DOI":"10.1074\/jbc.272.49.31079","volume":"272","author":"M Napiera\u0142a","year":"1997","unstructured":"Napiera\u0142a, M. & Krzyzosiak, W. J. CUG repeats present in myotonin kinase RNA form metastable \u201cslippery\u201d hairpins. J. Biol. Chem. 272, 31079\u201331085 (1997).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol2017148_CR145","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-3-540-34449-0_7","volume":"44","author":"NM Kuyumcu-Martinez","year":"2006","unstructured":"Kuyumcu-Martinez, N. M. & Cooper, T. A. Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. Prog. Mol. Subcell. Biol. 44, 133\u2013159 (2006).","journal-title":"Prog. Mol. Subcell. Biol."},{"key":"BFnrneurol2017148_CR146","first-page":"177","volume":"50","author":"R Cardani","year":"2006","unstructured":"Cardani, R., Mancinelli, E., Rotondo, G., Sansone, V. & Meola, G. Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2. Eur. J. Histochem. 50, 177\u2013182 (2006).","journal-title":"Eur. J. Histochem."},{"key":"BFnrneurol2017148_CR147","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1093\/nar\/29.13.2766","volume":"29","author":"M Fardaei","year":"2001","unstructured":"Fardaei, M., Larkin, K., Brook, J. D. & Hamshere, M. G. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res. 29, 2766\u20132771 (2001).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR148","first-page":"805","volume":"11","author":"M Fardaei","year":"2002","unstructured":"Fardaei, M. et al. Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum. Mol. Genet. 11, 805\u2013814 (2002).","journal-title":"Mol. Genet."},{"key":"BFnrneurol2017148_CR149","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1093\/hmg\/ddq277","volume":"19","author":"AJ Ward","year":"2010","unstructured":"Ward, A. J., Rimer, M., Killian, J. M., Dowling, J. J. & Cooper, T. A. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum. Mol. Genet. 19, 3614\u20133622 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol2017148_CR150","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.1093\/nar\/gkm601","volume":"35","author":"Y Yuan","year":"2007","unstructured":"Yuan, Y. et al. Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res. 35, 5474\u20135486 (2007).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR151","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/hmg\/ddp570","volume":"19","author":"M Koshelev","year":"2010","unstructured":"Koshelev, M., Sarma, S., Price, R. E., Wehrens, X. H. T. & Cooper, T. A. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum. Mol. Genet. 19, 1066\u20131075 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol2017148_CR152","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nsmb.1720","volume":"17","author":"H Du","year":"2010","unstructured":"Du, H. et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat. Struct. Mol. Biol. 17, 187\u2013193 (2010).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFnrneurol2017148_CR153","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1126\/science.1173110","volume":"325","author":"TM Wheeler","year":"2009","unstructured":"Wheeler, T. M. et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325, 336\u2013339 (2009).","journal-title":"Science"},{"key":"BFnrneurol2017148_CR154","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/sj.gt.3301955","volume":"10","author":"D Furling","year":"2003","unstructured":"Furling, D. et al. Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions. Gene Ther. 10, 795\u2013802 (2003).","journal-title":"Gene Ther."},{"key":"BFnrneurol2017148_CR155","doi-asserted-by":"publisher","first-page":"13915","DOI":"10.1073\/pnas.0905780106","volume":"106","author":"SAM Mulders","year":"2009","unstructured":"Mulders, S. A. M. et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc. Natl Acad. Sci. USA 106, 13915\u201313920 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR156","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1474-4422(12)70043-1","volume":"11","author":"E Majounie","year":"2012","unstructured":"Majounie, E. et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 11, 323\u2013330 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2017148_CR157","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245\u2013256 (2011).","journal-title":"Neuron"},{"key":"BFnrneurol2017148_CR158","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257\u2013268 (2011).","journal-title":"Neuron"},{"key":"BFnrneurol2017148_CR159","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.mcn.2012.12.006","volume":"56","author":"VV Belzil","year":"2013","unstructured":"Belzil, V. V., Gendron, T. F. & Petrucelli, L. RNA-mediated toxicity in neurodegenerative disease. Mol. Cell. Neurosci. 56, 406\u2013419 (2013).","journal-title":"Mol. Cell. Neurosci."},{"key":"BFnrneurol2017148_CR160","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1474-4422(11)70261-7","volume":"11","author":"I Gijselinck","year":"2012","unstructured":"Gijselinck, I. et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 11, 54\u201365 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2017148_CR161","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00401-014-1286-y","volume":"128","author":"EY Liu","year":"2014","unstructured":"Liu, E. Y. et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS\/FTD. Acta Neuropathol. 128, 525\u2013541 (2014).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2017148_CR162","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ajhg.2013.04.017","volume":"92","author":"Z Xi","year":"2013","unstructured":"Xi, Z. et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am. J. Hum. Genet. 92, 981\u2013989 (2013).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrneurol2017148_CR163","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00401-015-1401-8","volume":"129","author":"Z Xi","year":"2015","unstructured":"Xi, Z. et al. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathol. 129, 715\u2013727 (2015).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2017148_CR164","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00401-013-1237-z","volume":"127","author":"TF Gendron","year":"2014","unstructured":"Gendron, T. F., Belzil, V. V., Zhang, Y.-J. & Petrucelli, L. Mechanisms of toxicity in C9FTLD\/ALS. Acta Neuropathol. 127, 359\u2013376 (2014).","journal-title":"Acta Neuropathol."},{"key":"BFnrneurol2017148_CR165","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.neuron.2013.07.033","volume":"79","author":"S-C Ling","year":"2013","unstructured":"Ling, S.-C., Polymenidou, M. & Cleveland, D. W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416\u2013438 (2013).","journal-title":"Neuron"},{"key":"BFnrneurol2017148_CR166","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","volume":"90","author":"J Jiang","year":"2016","unstructured":"Jiang, J. et al. Gain of toxicity from ALS\/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron 90, 535\u2013550 (2016).","journal-title":"Neuron"},{"key":"BFnrneurol2017148_CR167","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1073\/pnas.1013343108","volume":"108","author":"T Zu","year":"2011","unstructured":"Zu, T. et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl Acad. Sci. USA 108, 260\u2013265 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR168","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1093\/hmg\/ddt371","volume":"22","author":"JD Cleary","year":"2013","unstructured":"Cleary, J. D. & Ranum, L. P. W. Repeat-associated non-ATG (RAN) translation in neurological disease. Hum. Mol. Genet. 22, R45\u2013R51 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol2017148_CR169","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fnmol.2017.00035","volume":"10","author":"BD Freibaum","year":"2017","unstructured":"Freibaum, B. D. & Taylor, J. P. The role of dipeptide repeats in C9ORF72-related ALS-FTD. Front. Mol. Neurosci. 10, 35 (2017).","journal-title":"Front. Mol. Neurosci."},{"key":"BFnrneurol2017148_CR170","doi-asserted-by":"publisher","first-page":"E4530","DOI":"10.1073\/pnas.1318835110","volume":"110","author":"C Lagier-Tourenne","year":"2013","unstructured":"Lagier-Tourenne, C. et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA 110, E4530\u2013E4539 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR171","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","volume":"80","author":"CJ Donnelly","year":"2013","unstructured":"Donnelly, C. J. et al. RNA toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415\u2013428 (2013).","journal-title":"Neuron"},{"key":"BFnrneurol2017148_CR172","volume-title":"GeneReviews\u00ae","author":"TW Prior","year":"2000","unstructured":"Prior, T. W. & Finanger, E. in GeneReviews\u00ae (eds Adam, M. P. et al.) Ch. Spinal Muscular Atrophy (University of Washington, 2000)."},{"key":"BFnrneurol2017148_CR173","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/344540a0","volume":"344","author":"LM Brzustowicz","year":"1990","unstructured":"Brzustowicz, L. M. et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q1 1.2\u201413.3. Nature 344, 540\u2013541 (1990).","journal-title":"Nature"},{"key":"BFnrneurol2017148_CR174","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","volume":"10","author":"AHM Burghes","year":"2009","unstructured":"Burghes, A. H. M. & Beattie, C. E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat. Rev. Neurosci. 10, 597\u2013609 (2009).","journal-title":"Nat. Rev. Neurosci."},{"key":"BFnrneurol2017148_CR175","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh, N. K., Singh, N. N., Androphy, E. J. & Singh, R. N. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol. 26, 1333\u20131346 (2006).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrneurol2017148_CR176","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/gt.2017.34","volume":"24","author":"NN Singh","year":"2017","unstructured":"Singh, N. N., Howell, M. D., Androphy, E. J. & Singh, R. N. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther. 24, 520\u2013526 (2017).","journal-title":"Gene Ther."},{"key":"BFnrneurol2017148_CR177","doi-asserted-by":"publisher","first-page":"7633","DOI":"10.1523\/JNEUROSCI.0950-09.2009","volume":"29","author":"JH Williams","year":"2009","unstructured":"Williams, J. H. et al. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J. Neurosci. 29, 7633\u20137638 (2009).","journal-title":"J. Neurosci."},{"key":"BFnrneurol2017148_CR178","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua, Y. et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 1634\u20131644 (2010).","journal-title":"Genes Dev."},{"key":"BFnrneurol2017148_CR179","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua, Y. et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478, 123\u2013126 (2011).","journal-title":"Nature"},{"key":"BFnrneurol2017148_CR180","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","volume":"21","author":"PN Porensky","year":"2012","unstructured":"Porensky, P. N. et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. Mol. Genet. 21, 1625\u20131638 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol2017148_CR181","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/hum.2012.211","volume":"24","author":"H Zhou","year":"2013","unstructured":"Zhou, H. et al. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum. Gene Ther. 24, 331\u2013342 (2013).","journal-title":"Hum. Gene Ther."},{"key":"BFnrneurol2017148_CR182","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fphys.2013.00356","volume":"4","author":"JG Boyer","year":"2013","unstructured":"Boyer, J. G., Ferrier, A. & Kothary, R. More than a bystander: the contributions of intrinsic skeletal muscle defects in motor neuron diseases. Front. Physiol. 4, 356 (2013).","journal-title":"Front. Physiol."},{"key":"BFnrneurol2017148_CR183","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0928-0987(00)00100-7","volume":"11","author":"L Smith","year":"2000","unstructured":"Smith, L., Andersen, K. B., Hovgaard, L. & Jaroszewski, J. W. Rational selection of antisense oligonucleotide sequences. Eur. J. Pharm. Sci. 11, 191\u2013198 (2000).","journal-title":"Eur. J. Pharm. Sci."},{"key":"BFnrneurol2017148_CR184","doi-asserted-by":"publisher","first-page":"e0120058","DOI":"10.1371\/journal.pone.0120058","volume":"10","author":"Y Echigoya","year":"2015","unstructured":"Echigoya, Y., Mouly, V., Garcia, L., Yokota, T. & Duddy, W. In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy. PLoS ONE 10, e0120058 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrneurol2017148_CR185","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nm.3765","volume":"21","author":"A Goyenvalle","year":"2015","unstructured":"Goyenvalle, A. et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat. Med. 21, 270\u2013275 (2015).","journal-title":"Nat. Med."},{"key":"BFnrneurol2017148_CR186","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt.3948","volume":"35","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto, N. et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat. Biotechnol. 35, 845\u2013851 (2017).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol2017148_CR187","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1602\/neurorx.2.4.554","volume":"2","author":"MS Alavijeh","year":"2005","unstructured":"Alavijeh, M. S., Chishty, M., Qaiser, M. Z. & Palmer, A. M. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx 2, 554\u2013571 (2005).","journal-title":"NeuroRx"},{"key":"BFnrneurol2017148_CR188","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1021\/mp3006006","volume":"10","author":"D Bedi","year":"2013","unstructured":"Bedi, D. et al. Targeted delivery of siRNA into breast cancer cells via phage fusion proteins. Mol. Pharm. 10, 551\u2013559 (2013).","journal-title":"Mol. Pharm."},{"key":"BFnrneurol2017148_CR189","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1089\/nat.2013.0450","volume":"24","author":"MS Falzarano","year":"2014","unstructured":"Falzarano, M. S., Passarelli, C. & Ferlini, A. Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid. Ther. 24, 87\u2013100 (2014).","journal-title":"Nucleic Acid. Ther."},{"key":"BFnrneurol2017148_CR190","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.addr.2016.06.008","volume":"106","author":"T Lehto","year":"2016","unstructured":"Lehto, T., Ezzat, K. & Wood, M. J. A. & EL Andaloussi, S. Peptides for nucleic acid delivery. Adv. Drug Deliv. Rev. 106, 172\u2013182 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"BFnrneurol2017148_CR191","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/nass\/nrn016","volume":"52","author":"GD Ivanova","year":"2008","unstructured":"Ivanova, G. D. et al. PNA-peptide conjugates as intracellular gene control agents. Nucleic Acids Symp. Ser. 52, 31\u201332 (2008).","journal-title":"Nucleic Acids Symp. Ser."},{"key":"BFnrneurol2017148_CR192","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/mt.2008.120","volume":"16","author":"N Jearawiriyapaisarn","year":"2008","unstructured":"Jearawiriyapaisarn, N. et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther. 16, 1624\u20131629 (2008).","journal-title":"Mol. Ther."},{"key":"BFnrneurol2017148_CR193","doi-asserted-by":"publisher","first-page":"14814","DOI":"10.1073\/pnas.0805676105","volume":"105","author":"B Wu","year":"2008","unstructured":"Wu, B. et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc. Natl Acad. Sci. USA 105, 14814\u201314819 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR194","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/mt.2011.79","volume":"19","author":"H Yin","year":"2011","unstructured":"Yin, H. et al. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther. 19, 1295\u20131303 (2011).","journal-title":"Mol. Ther."},{"key":"BFnrneurol2017148_CR195","doi-asserted-by":"publisher","first-page":"10962","DOI":"10.1073\/pnas.1605731113","volume":"113","author":"SM Hammond","year":"2016","unstructured":"Hammond, S. M. et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc. Natl Acad. Sci. USA 113, 10962\u201310967 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2017148_CR196","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0300-483X(97)03661-5","volume":"120","author":"SP Henry","year":"1997","unstructured":"Henry, S. P., Bolte, H., Auletta, C. & Kornbrust, D. J. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120, 145\u2013155 (1997).","journal-title":"Toxicology"},{"key":"BFnrneurol2017148_CR197","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1093\/nar\/gkq457","volume":"38","author":"EM Straarup","year":"2010","unstructured":"Straarup, E. M. et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 38, 7100\u20137111 (2010).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol2017148_CR198","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1006\/taap.1999.8771","volume":"160","author":"PL Iversen","year":"1999","unstructured":"Iversen, P. L., Cornish, K. G., Iversen, L. J., Mata, J. E. & Bylund, D. B. Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as \u03b11-adrenergic receptor antagonists. Toxicol. Appl. Pharmacol. 160, 289\u2013296 (1999).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"BFnrneurol2017148_CR199","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/nbt.2376","volume":"30","author":"M Lindow","year":"2012","unstructured":"Lindow, M. et al. Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat. Biotechnol. 30, 920\u2013923 (2012).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol2017148_CR200","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","volume":"364","author":"NM Goemans","year":"2011","unstructured":"Goemans, N. M. et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364, 1513\u20131522 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2017148_CR201","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01128855 (2017)."},{"key":"BFnrneurol2017148_CR202","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","volume":"13","author":"T Voit","year":"2014","unstructured":"Voit, T. et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 13, 987\u2013996 (2014).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2017148_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01254019 (2017)."},{"key":"BFnrneurol2017148_CR204","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01480245 (2017)."},{"key":"BFnrneurol2017148_CR205","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01462292 (2017)."},{"key":"BFnrneurol2017148_CR206","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01803412 (2016)."},{"key":"BFnrneurol2017148_CR207","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02636686 (2016)."},{"key":"BFnrneurol2017148_CR208","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","volume":"8","author":"M Kinali","year":"2009","unstructured":"Kinali, M., et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918\u2013928 (2009).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2017148_CR209","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01540409 (2016)."},{"key":"BFnrneurol2017148_CR210","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02255552 (2017)."},{"key":"BFnrneurol2017148_CR211","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02286947 (2017)."},{"key":"BFnrneurol2017148_CR212","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02420379 (2017)."},{"key":"BFnrneurol2017148_CR213","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01037309 (2015)."},{"key":"BFnrneurol2017148_CR214","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01826474 (2015)."},{"key":"BFnrneurol2017148_CR215","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02500381 (2017)."},{"key":"BFnrneurol2017148_CR216","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01494701 (2017)."},{"key":"BFnrneurol2017148_CR217","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01703988 (2017)."},{"key":"BFnrneurol2017148_CR218","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01780246 (2017)."},{"key":"BFnrneurol2017148_CR219","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02052791 (2017)."},{"key":"BFnrneurol2017148_CR220","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02193074 (2017)."},{"key":"BFnrneurol2017148_CR221","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02292537 (2017)."},{"key":"BFnrneurol2017148_CR222","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02386553 (2017)."},{"key":"BFnrneurol2017148_CR223","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02462759 (2017)."},{"key":"BFnrneurol2017148_CR224","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02594124 (2017)."},{"key":"BFnrneurol2017148_CR225","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02865109 (2017)."},{"key":"BFnrneurol2017148_CR226","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01737398 (2016)."},{"key":"BFnrneurol2017148_CR227","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02519036 (2017)."},{"key":"BFnrneurol2017148_CR228","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02623699 (2017)."},{"key":"BFnrneurol2017148_CR229","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1212\/WNL.0000000000000926","volume":"83","author":"V Limmroth","year":"2014","unstructured":"Limmroth, V. et al. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology 83, 1780\u20131788 (2014).","journal-title":"Neurology"},{"key":"BFnrneurol2017148_CR230","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02312011 (2016)."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2017.148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2017.148","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrneurol.2017.148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2017.148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:21:09Z","timestamp":1684455669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2017.148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":230,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFnrneurol2017148"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2017.148","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,1]]},"assertion":[{"value":"1 December 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.R. declares no competing interests. M.J.A.W., through the University of Oxford, has filed patents on peptide-based methods for antisense oligonucleotide delivery.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}